amitriptylinoxide
Small moleculeexperimental
Amitriptylinoxide, or amitriptyline N-oxide, is a tricyclic antidepressant (TCA) which was introduced in Europe in the 1970s for the treatment of depression. — Wikipedia
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
1
Earliest trial started Sep 1, 2011 (NCT02237937)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Norepinephrine transporterANTAGONIST
SC6A2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
C[N+](C)([O-])CCC=C1c2ccccc2CCc2ccccc21- Mol. weight
- 293.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAmitriptylinoxide ↗
- ChEMBLCHEMBL627 ↗
Also known as
- amioxid-neuraxpharm
- amitriptyline n-oxide
- amitriptyline n-oxide
- amitriptyline oxide
- amitriptyline oxide
- amitriptyline oxide
- amitriptylinoxide
- amitriptylinoxide
- amitriptylinoxide
- amitriptylinoxide
- amitriptylinoxide
- amitriptylinoxide
- amitriptylinoxide
- amitryptyline-n-oxide
- amitryptyline-n-oxide
- equilibrin
- neuraxpharm brand of amitriptylinoxide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02374567 | Phase 3 | Jan 1, 2015 | Gottfried Wilhelm Leibniz Universität Hannover |
| NCT02237937 | Phase 4 | Sep 1, 2011 | HolsboerMaschmeyer NeuroChemie GmbH, Max Planck Institute |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gottfried Wilhelm Leibniz Universität Hannover | Academic/Hospital | 1 | 1 | 1 | 2015 |
| HolsboerMaschmeyer NeuroChemie GmbH | For profit | 1 | 1 | 1 | 2011 |
| Max Planck Institute | Academic/Hospital | 1 | 0 | 1 | 2011 |
3 organizations
Page 1 / 1